Companies › OTLK

Outlook Therapeutics Inc (OTLK)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001649989 · EDGAR filings · Updated 2026-07-24

Outlook Therapeutics Inc (OTLK) has reported institutional ownership of 8.9%, with 54 institutional managers holding positions valued at $2.21M per the latest 13F reporting period. SEC filings include an active notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (4)

• 2026-07-24 — Current report (8-K) filed
• 2026-07-24 — Current report (8-K) filed
• 2026-07-23 — Insider transaction reported (Form 4)
• 2026-07-23 — Insider transaction reported (Form 4)

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-21 — EFFECT filed
• 2026-07-21 — Prospectus supplement (424B3) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Outlook Therapeutics Inc has 54 institutional holders and institutional ownership of 8.9%.

Insider activity

Insiders reported 1 transactions (0 buys, 0 sells) across 1 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

LONGEVERON INC (LGVN) · MIRA PHARMACEUTICALS INC COM (MIRA) · IMPACT BIOMEDICAL INC (IBO) · Q/C TECHNOLOGIES INC (QCLS) · SYNERGY CHC CORP (SNYR) · VIVOS THERAPEUTICS INC (VVOS)